Lun-Hua Chen1, He-Sheng Luo. 1. Department of Hematology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
Abstract
AIM: To elucidate the influences of H pylori infection on oral iron treatment for iron deficiency anemia (IDA). METHODS: A total of 86 patients were divided into two groups: group A, receiving ferrous succinate combined with triple therapy for H pylori eradication, and group B (control), treated with ferrous succinate only. During treatment of IDA, dynamic changes in hemoglobin (Hb) level, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), serum iron (SI), and serum ferritin (SF) were compared between the groups. RESULTS: Hb was slightly higher in group A at d 14 after the start of triple therapy for H pylori eradication (P > 0.05). After the therapy, the increase of Hb in group A became significantly faster than that in group B (P < 0.05). At d 56, the mean Hb in group A returned to the normal level, however, in group B, it was lower than that in group A (P < 0.05) although it had also increased compared with that before oral iron treatment. The MCV and MCH in group A recovered to the normal level, and were much higher than those in group B (P < 0.05) at d 21. In Group B, the MCV and MCH remained at lower than normal levels until d 42 after the start of therapy. And then, they reached a plateau in both groups and the differences disappeared (P > 0.05). The SF in group A was higher than that in group B (P < 0.05) 28 d after the treatment and its improvement was quicker in group A (P < 0.05) , and the difference between the two groups was even more significant (P < 0.01) at d 56. The SI in group A was higher than that in group B (P < 0.05) at d 14 and this persisted until d 56 when the follow-up of this research was finished. CONCLUSION: Treatment of H pylori can enhance the efficacy of ferrous succinate therapy in IDA patients with H pylori-positive chronic gastritis.
RCT Entities:
AIM: To elucidate the influences of H pylori infection on oral iron treatment for iron deficiency anemia (IDA). METHODS: A total of 86 patients were divided into two groups: group A, receiving ferrous succinate combined with triple therapy for H pylori eradication, and group B (control), treated with ferrous succinate only. During treatment of IDA, dynamic changes in hemoglobin (Hb) level, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), serum iron (SI), and serum ferritin (SF) were compared between the groups. RESULTS: Hb was slightly higher in group A at d 14 after the start of triple therapy for H pylori eradication (P > 0.05). After the therapy, the increase of Hb in group A became significantly faster than that in group B (P < 0.05). At d 56, the mean Hb in group A returned to the normal level, however, in group B, it was lower than that in group A (P < 0.05) although it had also increased compared with that before oral iron treatment. The MCV and MCH in group A recovered to the normal level, and were much higher than those in group B (P < 0.05) at d 21. In Group B, the MCV and MCH remained at lower than normal levels until d 42 after the start of therapy. And then, they reached a plateau in both groups and the differences disappeared (P > 0.05). The SF in group A was higher than that in group B (P < 0.05) 28 d after the treatment and its improvement was quicker in group A (P < 0.05) , and the difference between the two groups was even more significant (P < 0.01) at d 56. The SI in group A was higher than that in group B (P < 0.05) at d 14 and this persisted until d 56 when the follow-up of this research was finished. CONCLUSION: Treatment of H pylori can enhance the efficacy of ferrous succinate therapy in IDA patients with H pylori-positive chronic gastritis.
Authors: T Furuta; S Baba; M Takashima; H Futami; H Arai; M Kajimura; H Hanai; E Kaneko Journal: Scand J Gastroenterol Date: 1998-04 Impact factor: 2.423
Authors: G Capurso; E Lahner; A Marcheggiano; P Caruana; A Carnuccio; C Bordi; G Delle Fave; B Annibale Journal: Aliment Pharmacol Ther Date: 2001-11 Impact factor: 8.171
Authors: Sayed Amir Mirbagheri; Amir Ali Sohrabpour; Mehrdad Hasibi; Babak Moghimi; Mehdi Mohamadnejad Journal: World J Gastroenterol Date: 2005-03-21 Impact factor: 5.742
Authors: A J Parkinson; B D Gold; L Bulkow; R B Wainwright; B Swaminathan; B Khanna; K M Petersen; M A Fitzgerald Journal: Clin Diagn Lab Immunol Date: 2000-11
Authors: Jae H Park; Su Y Kim; Dong W Kim; Woo G Lee; Kwang H Rhee; Hee S Youn Journal: J Pediatr Gastroenterol Nutr Date: 2003-07 Impact factor: 2.839
Authors: Karen Miernyk; Dana Bruden; Carolyn Zanis; Brian McMahon; Frank Sacco; Thomas Hennessy; Alan Parkinson; Michael Bruce Journal: Helicobacter Date: 2013-01-15 Impact factor: 5.753
Authors: Wolfgang Fischbach; Peter Malfertheiner; Jörg C Hoffmann; Wolfgang Bolten; Manfred Kist; Sibylle Koletzko Journal: Dtsch Arztebl Int Date: 2009-12-04 Impact factor: 5.594
Authors: Rui Qi Chong; Ingrid Gelissen; Betty Chaar; Jonathan Penm; Janet My Cheung; Joanna E Harnett Journal: Explor Res Clin Soc Pharm Date: 2021-09-03